Proteinuria
Conditions
Interventions
Observational group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with primary IgA nephropathy (IgAN) through renal biopsy. 2. Age >=18 years old. 3. Have received Nefecon treatment for at least 6 months
Exclusion criteria
Exclusion criteria: 1. Missing baseline data or follow-up < 6 months; 2. Age < 18 years at baseline. 3. History of kidney transplantation or dialysis; 4. Secondary IgAN or non-IgAN glomerulonephritis; 5. History of kidney transplantation or dialysis; 6. Pregnancy at baseline or during follow-up;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in proteinuria-related parameters (24-hour urine protein quantification, urine protein-to-creatinine ratio, urine albumin-to-creatinine ratio);Improvement in renal function parameters (serum creatinine, estimated glomerular filtration rate);Changes in serum immunological markers (IgA, IgG, IgM, C3, C4, etc.);Differences in efficacy between the Nafurciclib group and the conventional treatment control group;Differences in efficacy among patient subgroups (proteinuria subtypes, histological Oxford classification, time since renal biopsy);Long-term prognostic outcomes including renal function progression, risk of end-stage renal disease (ESRD), and survival time; | — |
Countries
China
Contacts
Public ContactChen Chaosheng
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed